Health-related quality of life in patients with multiple myeloma treated in the phase 3 ATLAS trial of post-transplant maintenance with carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone.

Health-related quality of life in patients with multiple myeloma treated in the phase 3 ATLAS trial of post-transplant maintenance with carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone. Pol Arch Intern Med. 2024 05 28; 134(5).

View in: PubMed

subject areas

Aged
Antineoplastic Combined Chemotherapy Protocols
Dexamethasone
Female
Humans
Male
Middle Aged
Multiple Myeloma
Oligopeptides
Quality of Life
Thalidomide

authors with profiles

Benjamin Derman
Andrzej Jakubowiak